扶正消癌合剂联合GP方案治疗晚期非小细胞肺癌

邓晓明; 杜纪英; 曾琛; 古兆森; 杜延军; 王淑玲

您当前的位置：

首页 >

文章列表页 >

扶正消癌合剂联合GP方案治疗晚期非小细胞肺癌

更新时间：2024-01-04

- 扶正消癌合剂联合GP方案治疗晚期非小细胞肺癌
- Clinical Effect Observation of Fuzheng Xiaoai Mixture Combined with Chemotherapy of GP Regimen in Treating Patients with Advanced Non-samll Cell Lung Cancer
- 中国实验方剂学杂志 2012年18卷第22期页码：328-331
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号：
- 纸质出版日期：2012
- 稿件说明：
移动端阅览
邓晓明, 杜纪英, 曾琛, 等. 扶正消癌合剂联合GP方案治疗晚期非小细胞肺癌[J]. 中国实验方剂学杂志, 2012,18(22):328-331.

DENG Xiao-ming, DU Ji-ying, ZENG Chen, et al. Clinical Effect Observation of Fuzheng Xiaoai Mixture Combined with Chemotherapy of GP Regimen in Treating Patients with Advanced Non-samll Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(22): 328-331.
邓晓明, 杜纪英, 曾琛, 等. 扶正消癌合剂联合GP方案治疗晚期非小细胞肺癌[J]. 中国实验方剂学杂志, 2012,18(22):328-331. DOI：

DENG Xiao-ming, DU Ji-ying, ZENG Chen, et al. Clinical Effect Observation of Fuzheng Xiaoai Mixture Combined with Chemotherapy of GP Regimen in Treating Patients with Advanced Non-samll Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(22): 328-331. DOI：

摘要

目的: 观察扶正消癌合剂联合GP(吉西他滨+顺铂)方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法: 将60例晚期NSCLC患者随机分为两组各30例。对照组采用GP(吉西他滨1.0 g·m-2

第1

8天静脉滴注;顺铂20 mg·m-2

第1天静脉滴注)方案治疗

治疗组给予GP方案联合扶正消癌合剂(早晚各温服1袋

200 mL/袋)治疗。均21 d为1周期

至少化疗2周期。结果: 治疗组与对照组的有效率分别是23.33%

16.67%

两组差异无统计学意义。但在生活质量评分、免疫功能、中医证候改善、毒副反应发生率及外周血VEGF(血管内皮生长因子)水平的改变差异有统计学意义(P<0.05)。结论: 扶正消癌合剂联合GP方案可以改善晚期非小细胞肺癌患者的生活质量、免疫功能且可以减毒增效。

Abstract

Objective:To observe the clinical efficacy of Fuzheng Xiaoai mixture combined with gemcitabine-ciplatimon(GP) regimen in the treatment of advanced non-small cell lung cancer(NSCLC). Method: Sixty patients with advanced NSCLC were randomized into two groups

each 30 cases. The control group was treated with GP regimen

the treatment group was trea-ted with Fuzheng Xiaoai mixture combined with GP program. A treatment cycle lasted 21 days

at least two cycles. Result: The effective rate was 23.33%

16.67% in the treatment group and the control group

respectively

but there was no significant difference between two groups. But the treatment group has significant differences compared with the control group in the quality of life score

immune function

toxicity and adverse in-cidence

and the change of VEGF levels in peripheral blood (P<0.05). Conclusion: Fuzheng Xiaoai mixture combined with GP program can improve the quality of life in advanced non-small cell lung cancer patients

immune function and can reduce toxicity and increase efficiency.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

清燥救肺汤加减对晚期非小细胞肺癌化疗患者生活质量和生存期的影响

艾迪注射液联合化疗治疗晚期非小细胞肺癌

参附注射液联合含铂一线化疗方案治疗非小细胞肺癌的Meta分析

沙参麦冬汤加减联合化疗治疗非小细胞肺癌的Meta分析

中医辨证论治联合化疗治疗晚期非小细胞肺癌的Meta分析